ASTELLAS PHARMA EBITDA vs. Revenue

YPHA Stock  EUR 9.45  0.05  0.53%   
Based on the key profitability measurements obtained from ASTELLAS PHARMA's financial statements, ASTELLAS PHARMA UNSPADR may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess ASTELLAS PHARMA's ability to earn profits and add value for shareholders.
For ASTELLAS PHARMA profitability analysis, we use financial ratios and fundamental drivers that measure the ability of ASTELLAS PHARMA to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well ASTELLAS PHARMA UNSPADR utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between ASTELLAS PHARMA's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of ASTELLAS PHARMA UNSPADR over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Please note, there is a significant difference between ASTELLAS PHARMA's value and its price as these two are different measures arrived at by different means. Investors typically determine if ASTELLAS PHARMA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ASTELLAS PHARMA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

ASTELLAS PHARMA UNSPADR Revenue vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining ASTELLAS PHARMA's current stock value. Our valuation model uses many indicators to compare ASTELLAS PHARMA value to that of its competitors to determine the firm's financial worth.
JavaScript chart by amCharts 3.21.15751SL4YPHA 0200B400B600B800B1T1.2T1.4T1.6T 050B100B150B200B250B300B350B
ASTELLAS PHARMA UNSPADR is rated first in ebitda category among its peers. It is rated first in revenue category among its peers totaling about  4.04  of Revenue per EBITDA. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ASTELLAS PHARMA's earnings, one of the primary drivers of an investment's value.

ASTELLAS Revenue vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

ASTELLAS PHARMA

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
348.55 B
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

ASTELLAS PHARMA

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
1.41 T
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

ASTELLAS Revenue vs Competition

ASTELLAS PHARMA UNSPADR is rated first in revenue category among its peers. Market size based on revenue of Drug Manufacturers—General industry is at this time estimated at about 1.41 Trillion. ASTELLAS PHARMA totals roughly 1.41 Trillion in revenue claiming about 100% of equities under Drug Manufacturers—General industry.
JavaScript chart by amCharts 3.21.15ZSLSL4751MGCYPHA

ASTELLAS PHARMA Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in ASTELLAS PHARMA, profitability is also one of the essential criteria for including it into their portfolios because, without profit, ASTELLAS PHARMA will eventually generate negative long term returns. The profitability progress is the general direction of ASTELLAS PHARMA's change in net profit over the period of time. It can combine multiple indicators of ASTELLAS PHARMA, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Astellas Pharma Inc. engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas Pharma Inc. was founded in 1923 and is headquartered in Tokyo, Japan. ASTELLAS PHARMA operates under Drug ManufacturersGeneral classification in Germany and is traded on Frankfurt Stock Exchange. It employs 15455 people.

ASTELLAS Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on ASTELLAS PHARMA. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of ASTELLAS PHARMA position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the ASTELLAS PHARMA's important profitability drivers and their relationship over time.

Use ASTELLAS PHARMA in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ASTELLAS PHARMA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ASTELLAS PHARMA will appreciate offsetting losses from the drop in the long position's value.

ASTELLAS PHARMA Pair Trading

ASTELLAS PHARMA UNSPADR Pair Trading Analysis

The ability to find closely correlated positions to ASTELLAS PHARMA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ASTELLAS PHARMA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ASTELLAS PHARMA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ASTELLAS PHARMA UNSPADR to buy it.
The correlation of ASTELLAS PHARMA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ASTELLAS PHARMA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ASTELLAS PHARMA UNSPADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ASTELLAS PHARMA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your ASTELLAS PHARMA position

In addition to having ASTELLAS PHARMA in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Commodities ETFs Thematic Idea Now

Broad Commodities ETFs
Broad Commodities ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in ASTELLAS Stock

To fully project ASTELLAS PHARMA's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of ASTELLAS PHARMA UNSPADR at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include ASTELLAS PHARMA's income statement, its balance sheet, and the statement of cash flows.
Potential ASTELLAS PHARMA investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although ASTELLAS PHARMA investors may work on each financial statement separately, they are all related. The changes in ASTELLAS PHARMA's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ASTELLAS PHARMA's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Trending Assets

SL4
BRAGG GAMING GRP
3.42  -0.06  -1.72 
45P
PLAYMATES TOYS
0.07  0  1.54 
MGC
MGIC INVESTMENT
23.80  0.40  1.71 
H3M
HOCHSCHILD MINING
2.75  -0.16  -5.5